Anadis to commercialise BioGard
Thursday, 04 September, 2008
Anadis [ASX: ANX] is to begin commercialisation of BioGard, a treatment designed to maintain gastrointestinal and immune system health.
The treatment, aimed at people undergoing antiretroviral therapy for HIV/AIDS, will be marketed as medical food.
BioGard's active ingredient is a formulation of antigen-targeted Bovine Clostrum Powder (BCP). The cows from which the powder is sourced will be vaccinated with a mixture of lipopolysaccarides implicated as key drivers of AIDS pathogenesis.
It will at first be made available in tablet form, sold over-the-counter but intended for use under medical supervision.
The product's ingredients and manufacturing process has been approved by the TGA.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
